The cellular origins of drug resistance in cancer
Crossref DOI link: https://doi.org/10.1038/nm.4058
Published Online: 2016-03-03
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Oxnard, Geoffrey R
Text and Data Mining valid from 2016-03-01
Article History
First Online: 3 March 2016
Competing interests
: G.R.O. has received consulting fees from Ariad, AstraZeneca, Boehringer-Ingehleim, Clovis and Genentech.